Myriocin is derived from ascomycete Isaria sinclairii. Myriocin is the parent compound of fingolimod, an immunosuppressive sphingosine-1 receptor inhibitor. Myriocin exhibits both immunosuppressive and anticancer activities. This compound inhibits serine palmitoyltransferase, preventing sphingolipid formation. In vitro, myriocin decreases expression of cylin B1, cdc2, and cdc25C and increase expression of p53 and p21, inducing G2/M phase cell cycle arrest and inhibiting growth of melanoma cells. In animal models, myriocin decreases levels of CD4+ lymphocytes and alters the total lymphocyte populations.